Star Equity Holdings, Inc. (STRR) Stock Competitors & Peer Comparison
See (STRR) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| STRR | $11.04 | +0.18% | 40.9M | -11.64 | -$0.95 | N/A |
| DHR-PB | $1,261.26 | -0.78% | 916.8B | 146.01 | $8.64 | +0.72% |
| TMO | $492.20 | +4.87% | 182.9B | 21.25 | $23.16 | +0.37% |
| DHR | $188.87 | +5.53% | 133.7B | 23.67 | $7.98 | +0.72% |
| IDXX | $549.16 | +1.45% | 43.3B | 40.44 | $13.58 | N/A |
| NTRA | $259.97 | +10.74% | 37.2B | -163.50 | -$1.59 | N/A |
| A | $131.63 | +3.92% | 37.2B | 22.65 | $5.81 | +0.77% |
| IQV | $185.62 | +8.37% | 31B | 15.31 | $12.13 | N/A |
| ILMN | $175.09 | +6.16% | 26.5B | 34.80 | $5.03 | N/A |
| MTD | $1,203.18 | +4.02% | 24.3B | 27.66 | $43.51 | N/A |
Stock Comparison
STRR vs DHR-PB Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, STRR is priced at $11.04, while DHR-PB trades at $1,261.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, STRR's ROE is -0.14%, compared to DHR-PB's ROE of +0.07%. Regarding short-term risk, STRR is more volatile compared to DHR-PB. This indicates potentially higher risk in terms of short-term price fluctuations for STRR.Check DHR-PB's competition here
STRR vs TMO Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, TMO has a market cap of 182.9B. Regarding current trading prices, STRR is priced at $11.04, while TMO trades at $492.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas TMO's P/E ratio is 21.25. In terms of profitability, STRR's ROE is -0.14%, compared to TMO's ROE of +0.13%. Regarding short-term risk, STRR is less volatile compared to TMO. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check TMO's competition here
STRR vs DHR Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, DHR has a market cap of 133.7B. Regarding current trading prices, STRR is priced at $11.04, while DHR trades at $188.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas DHR's P/E ratio is 23.67. In terms of profitability, STRR's ROE is -0.14%, compared to DHR's ROE of +0.07%. Regarding short-term risk, STRR is less volatile compared to DHR. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check DHR's competition here
STRR vs IDXX Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, IDXX has a market cap of 43.3B. Regarding current trading prices, STRR is priced at $11.04, while IDXX trades at $549.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas IDXX's P/E ratio is 40.44. In terms of profitability, STRR's ROE is -0.14%, compared to IDXX's ROE of +0.71%. Regarding short-term risk, STRR is less volatile compared to IDXX. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check IDXX's competition here
STRR vs NTRA Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, NTRA has a market cap of 37.2B. Regarding current trading prices, STRR is priced at $11.04, while NTRA trades at $259.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas NTRA's P/E ratio is -163.50. In terms of profitability, STRR's ROE is -0.14%, compared to NTRA's ROE of -0.15%. Regarding short-term risk, STRR is less volatile compared to NTRA. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check NTRA's competition here
STRR vs A Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, A has a market cap of 37.2B. Regarding current trading prices, STRR is priced at $11.04, while A trades at $131.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas A's P/E ratio is 22.65. In terms of profitability, STRR's ROE is -0.14%, compared to A's ROE of +0.21%. Regarding short-term risk, STRR is less volatile compared to A. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check A's competition here
STRR vs IQV Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, IQV has a market cap of 31B. Regarding current trading prices, STRR is priced at $11.04, while IQV trades at $185.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas IQV's P/E ratio is 15.31. In terms of profitability, STRR's ROE is -0.14%, compared to IQV's ROE of +0.22%. Regarding short-term risk, STRR is less volatile compared to IQV. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check IQV's competition here
STRR vs ILMN Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, ILMN has a market cap of 26.5B. Regarding current trading prices, STRR is priced at $11.04, while ILMN trades at $175.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas ILMN's P/E ratio is 34.80. In terms of profitability, STRR's ROE is -0.14%, compared to ILMN's ROE of +0.34%. Regarding short-term risk, STRR is less volatile compared to ILMN. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check ILMN's competition here
STRR vs MTD Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, MTD has a market cap of 24.3B. Regarding current trading prices, STRR is priced at $11.04, while MTD trades at $1,203.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas MTD's P/E ratio is 27.66. In terms of profitability, STRR's ROE is -0.14%, compared to MTD's ROE of -6.10%. Regarding short-term risk, STRR is less volatile compared to MTD. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check MTD's competition here
STRR vs WAT Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, WAT has a market cap of 24.1B. Regarding current trading prices, STRR is priced at $11.04, while WAT trades at $369.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas WAT's P/E ratio is 27.17. In terms of profitability, STRR's ROE is -0.14%, compared to WAT's ROE of +0.08%. Regarding short-term risk, STRR is less volatile compared to WAT. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check WAT's competition here
STRR vs DGX Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, DGX has a market cap of 22.5B. Regarding current trading prices, STRR is priced at $11.04, while DGX trades at $203.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas DGX's P/E ratio is 20.03. In terms of profitability, STRR's ROE is -0.14%, compared to DGX's ROE of +0.14%. Regarding short-term risk, STRR is less volatile compared to DGX. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check DGX's competition here
STRR vs LH Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, LH has a market cap of 21.7B. Regarding current trading prices, STRR is priced at $11.04, while LH trades at $265.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas LH's P/E ratio is 15.74. In terms of profitability, STRR's ROE is -0.14%, compared to LH's ROE of +0.11%. Regarding short-term risk, STRR is less volatile compared to LH. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check LH's competition here
STRR vs EXAS Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, EXAS has a market cap of 20B. Regarding current trading prices, STRR is priced at $11.04, while EXAS trades at $104.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas EXAS's P/E ratio is -95.37. In terms of profitability, STRR's ROE is -0.14%, compared to EXAS's ROE of -0.09%. Regarding short-term risk, STRR is more volatile compared to EXAS. This indicates potentially higher risk in terms of short-term price fluctuations for STRR.Check EXAS's competition here
STRR vs GH Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, GH has a market cap of 18.2B. Regarding current trading prices, STRR is priced at $11.04, while GH trades at $136.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas GH's P/E ratio is -53.09. In terms of profitability, STRR's ROE is -0.14%, compared to GH's ROE of +1.84%. Regarding short-term risk, STRR is less volatile compared to GH. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check GH's competition here
STRR vs ILMNV Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, ILMNV has a market cap of 17B. Regarding current trading prices, STRR is priced at $11.04, while ILMNV trades at $107.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas ILMNV's P/E ratio is N/A. In terms of profitability, STRR's ROE is -0.14%, compared to ILMNV's ROE of N/A. Regarding short-term risk, STRR is more volatile compared to ILMNV. This indicates potentially higher risk in terms of short-term price fluctuations for STRR.Check ILMNV's competition here
STRR vs MEDP Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, MEDP has a market cap of 14.6B. Regarding current trading prices, STRR is priced at $11.04, while MEDP trades at $512.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas MEDP's P/E ratio is 32.23. In terms of profitability, STRR's ROE is -0.14%, compared to MEDP's ROE of +1.21%. Regarding short-term risk, STRR is less volatile compared to MEDP. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check MEDP's competition here
STRR vs PKI Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, PKI has a market cap of 14.5B. Regarding current trading prices, STRR is priced at $11.04, while PKI trades at $115.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas PKI's P/E ratio is 41.45. In terms of profitability, STRR's ROE is -0.14%, compared to PKI's ROE of +0.03%. Regarding short-term risk, STRR is less volatile compared to PKI. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check PKI's competition here
STRR vs ICLR Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, ICLR has a market cap of 12.1B. Regarding current trading prices, STRR is priced at $11.04, while ICLR trades at $158.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas ICLR's P/E ratio is 12.90. In terms of profitability, STRR's ROE is -0.14%, compared to ICLR's ROE of +0.05%. Regarding short-term risk, STRR is less volatile compared to ICLR. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check ICLR's competition here
STRR vs RVTY Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, RVTY has a market cap of 11.8B. Regarding current trading prices, STRR is priced at $11.04, while RVTY trades at $105.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas RVTY's P/E ratio is 20.66. In terms of profitability, STRR's ROE is -0.14%, compared to RVTY's ROE of +0.03%. Regarding short-term risk, STRR is less volatile compared to RVTY. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check RVTY's competition here
STRR vs CRL Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, CRL has a market cap of 9.7B. Regarding current trading prices, STRR is priced at $11.04, while CRL trades at $202.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas CRL's P/E ratio is 20.20. In terms of profitability, STRR's ROE is -0.14%, compared to CRL's ROE of -0.06%. Regarding short-term risk, STRR is less volatile compared to CRL. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check CRL's competition here
STRR vs QGEN Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, QGEN has a market cap of 8B. Regarding current trading prices, STRR is priced at $11.04, while QGEN trades at $38.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas QGEN's P/E ratio is 19.77. In terms of profitability, STRR's ROE is -0.14%, compared to QGEN's ROE of +0.11%. Regarding short-term risk, STRR is less volatile compared to QGEN. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check QGEN's competition here
STRR vs TWST Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, TWST has a market cap of 5.7B. Regarding current trading prices, STRR is priced at $11.04, while TWST trades at $91.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas TWST's P/E ratio is -44.78. In terms of profitability, STRR's ROE is -0.14%, compared to TWST's ROE of -0.17%. Regarding short-term risk, STRR is less volatile compared to TWST. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check TWST's competition here
STRR vs BLLN Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, BLLN has a market cap of 4.9B. Regarding current trading prices, STRR is priced at $11.04, while BLLN trades at $107.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas BLLN's P/E ratio is 195.55. In terms of profitability, STRR's ROE is -0.14%, compared to BLLN's ROE of +0.08%. Regarding short-term risk, STRR is less volatile compared to BLLN. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check BLLN's competition here
STRR vs SHC Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, SHC has a market cap of 4.8B. Regarding current trading prices, STRR is priced at $11.04, while SHC trades at $16.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas SHC's P/E ratio is 18.54. In terms of profitability, STRR's ROE is -0.14%, compared to SHC's ROE of +0.21%. Regarding short-term risk, STRR is less volatile compared to SHC. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check SHC's competition here
STRR vs RDNT Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, RDNT has a market cap of 4.6B. Regarding current trading prices, STRR is priced at $11.04, while RDNT trades at $58.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas RDNT's P/E ratio is 126.43. In terms of profitability, STRR's ROE is -0.14%, compared to RDNT's ROE of -0.01%. Regarding short-term risk, STRR is less volatile compared to RDNT. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check RDNT's competition here
STRR vs SYNH Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, SYNH has a market cap of 4.5B. Regarding current trading prices, STRR is priced at $11.04, while SYNH trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas SYNH's P/E ratio is 61.40. In terms of profitability, STRR's ROE is -0.14%, compared to SYNH's ROE of +0.08%. Regarding short-term risk, STRR is more volatile compared to SYNH. This indicates potentially higher risk in terms of short-term price fluctuations for STRR.Check SYNH's competition here
STRR vs OLK Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, OLK has a market cap of 3.2B. Regarding current trading prices, STRR is priced at $11.04, while OLK trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas OLK's P/E ratio is -96.59. In terms of profitability, STRR's ROE is -0.14%, compared to OLK's ROE of -0.07%. Regarding short-term risk, STRR is more volatile compared to OLK. This indicates potentially higher risk in terms of short-term price fluctuations for STRR.Check OLK's competition here
STRR vs GRAL Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, GRAL has a market cap of 2.8B. Regarding current trading prices, STRR is priced at $11.04, while GRAL trades at $64.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas GRAL's P/E ratio is -6.27. In terms of profitability, STRR's ROE is -0.14%, compared to GRAL's ROE of -0.16%. Regarding short-term risk, STRR is less volatile compared to GRAL. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check GRAL's competition here
STRR vs NEOG Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, NEOG has a market cap of 2B. Regarding current trading prices, STRR is priced at $11.04, while NEOG trades at $9.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas NEOG's P/E ratio is 32.79. In terms of profitability, STRR's ROE is -0.14%, compared to NEOG's ROE of -0.29%. Regarding short-term risk, STRR is less volatile compared to NEOG. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check NEOG's competition here
STRR vs CDNA Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, CDNA has a market cap of 1.4B. Regarding current trading prices, STRR is priced at $11.04, while CDNA trades at $27.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas CDNA's P/E ratio is 32.30. In terms of profitability, STRR's ROE is -0.14%, compared to CDNA's ROE of -0.03%. Regarding short-term risk, STRR is less volatile compared to CDNA. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check CDNA's competition here
STRR vs PSNL Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, PSNL has a market cap of 1B. Regarding current trading prices, STRR is priced at $11.04, while PSNL trades at $11.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas PSNL's P/E ratio is -11.14. In terms of profitability, STRR's ROE is -0.14%, compared to PSNL's ROE of -0.44%. Regarding short-term risk, STRR is less volatile compared to PSNL. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check PSNL's competition here
STRR vs CSTL Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, CSTL has a market cap of 671.8M. Regarding current trading prices, STRR is priced at $11.04, while CSTL trades at $22.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas CSTL's P/E ratio is -50.34. In terms of profitability, STRR's ROE is -0.14%, compared to CSTL's ROE of -0.03%. Regarding short-term risk, STRR is less volatile compared to CSTL. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check CSTL's competition here
STRR vs GRALV Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, GRALV has a market cap of 579.4M. Regarding current trading prices, STRR is priced at $11.04, while GRALV trades at $18.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas GRALV's P/E ratio is N/A. In terms of profitability, STRR's ROE is -0.14%, compared to GRALV's ROE of N/A. Regarding short-term risk, STRR is less volatile compared to GRALV. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check GRALV's competition here
STRR vs FLGT Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, FLGT has a market cap of 543.3M. Regarding current trading prices, STRR is priced at $11.04, while FLGT trades at $19.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas FLGT's P/E ratio is -7.97. In terms of profitability, STRR's ROE is -0.14%, compared to FLGT's ROE of -0.07%. Regarding short-term risk, STRR is less volatile compared to FLGT. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check FLGT's competition here
STRR vs MYGN Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, MYGN has a market cap of 493M. Regarding current trading prices, STRR is priced at $11.04, while MYGN trades at $5.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas MYGN's P/E ratio is -1.21. In terms of profitability, STRR's ROE is -0.14%, compared to MYGN's ROE of -1.09%. Regarding short-term risk, STRR is less volatile compared to MYGN. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check MYGN's competition here
STRR vs CO Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, CO has a market cap of 400.1M. Regarding current trading prices, STRR is priced at $11.04, while CO trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas CO's P/E ratio is 5.06. In terms of profitability, STRR's ROE is -0.14%, compared to CO's ROE of +0.11%. Regarding short-term risk, STRR is less volatile compared to CO. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check CO's competition here
STRR vs NEO Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, NEO has a market cap of 335.9M. Regarding current trading prices, STRR is priced at $11.04, while NEO trades at $12.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas NEO's P/E ratio is 99.23. In terms of profitability, STRR's ROE is -0.14%, compared to NEO's ROE of -0.12%. Regarding short-term risk, STRR is less volatile compared to NEO. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check NEO's competition here
STRR vs PRE Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, PRE has a market cap of 335.2M. Regarding current trading prices, STRR is priced at $11.04, while PRE trades at $19.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas PRE's P/E ratio is -9.57. In terms of profitability, STRR's ROE is -0.14%, compared to PRE's ROE of -0.47%. Regarding short-term risk, STRR is less volatile compared to PRE. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check PRE's competition here
STRR vs FLDM Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, FLDM has a market cap of 294.2M. Regarding current trading prices, STRR is priced at $11.04, while FLDM trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas FLDM's P/E ratio is -4.74. In terms of profitability, STRR's ROE is -0.14%, compared to FLDM's ROE of +0.17%. Regarding short-term risk, STRR is less volatile compared to FLDM. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check FLDM's competition here
STRR vs BDSX Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, BDSX has a market cap of 152M. Regarding current trading prices, STRR is priced at $11.04, while BDSX trades at $18.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas BDSX's P/E ratio is -4.60. In terms of profitability, STRR's ROE is -0.14%, compared to BDSX's ROE of -21.01%. Regarding short-term risk, STRR is less volatile compared to BDSX. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check BDSX's competition here
STRR vs IMDX Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, IMDX has a market cap of 145.5M. Regarding current trading prices, STRR is priced at $11.04, while IMDX trades at $5.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas IMDX's P/E ratio is -4.55. In terms of profitability, STRR's ROE is -0.14%, compared to IMDX's ROE of +3.81%. Regarding short-term risk, STRR is less volatile compared to IMDX. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check IMDX's competition here
STRR vs GTH Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, GTH has a market cap of 127.3M. Regarding current trading prices, STRR is priced at $11.04, while GTH trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas GTH's P/E ratio is -1.11. In terms of profitability, STRR's ROE is -0.14%, compared to GTH's ROE of -1.01%. Regarding short-term risk, STRR is more volatile compared to GTH. This indicates potentially higher risk in terms of short-term price fluctuations for STRR.Check GTH's competition here
STRR vs GENE Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, GENE has a market cap of 111.2M. Regarding current trading prices, STRR is priced at $11.04, while GENE trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas GENE's P/E ratio is -38.25. In terms of profitability, STRR's ROE is -0.14%, compared to GENE's ROE of -1.85%. Regarding short-term risk, STRR is more volatile compared to GENE. This indicates potentially higher risk in terms of short-term price fluctuations for STRR.Check GENE's competition here
STRR vs XGN Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, XGN has a market cap of 109.2M. Regarding current trading prices, STRR is priced at $11.04, while XGN trades at $4.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas XGN's P/E ratio is -6.11. In terms of profitability, STRR's ROE is -0.14%, compared to XGN's ROE of -1.14%. Regarding short-term risk, STRR is less volatile compared to XGN. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check XGN's competition here
STRR vs STIM Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, STIM has a market cap of 87.7M. Regarding current trading prices, STRR is priced at $11.04, while STIM trades at $1.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas STIM's P/E ratio is -2.33. In terms of profitability, STRR's ROE is -0.14%, compared to STIM's ROE of -1.65%. Regarding short-term risk, STRR is less volatile compared to STIM. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check STIM's competition here
STRR vs SERA Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, SERA has a market cap of 70.5M. Regarding current trading prices, STRR is priced at $11.04, while SERA trades at $1.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas SERA's P/E ratio is -2.84. In terms of profitability, STRR's ROE is -0.14%, compared to SERA's ROE of -0.41%. Regarding short-term risk, STRR is less volatile compared to SERA. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check SERA's competition here
STRR vs ATLN Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, ATLN has a market cap of 59.5M. Regarding current trading prices, STRR is priced at $11.04, while ATLN trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas ATLN's P/E ratio is -0.59. In terms of profitability, STRR's ROE is -0.14%, compared to ATLN's ROE of +38.02%. Regarding short-term risk, STRR is less volatile compared to ATLN. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check ATLN's competition here
STRR vs DRIO Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, DRIO has a market cap of 44.5M. Regarding current trading prices, STRR is priced at $11.04, while DRIO trades at $6.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas DRIO's P/E ratio is -1.04. In terms of profitability, STRR's ROE is -0.14%, compared to DRIO's ROE of +0.93%. Regarding short-term risk, STRR is less volatile compared to DRIO. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check DRIO's competition here
STRR vs STRRP Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, STRRP has a market cap of 41.2M. Regarding current trading prices, STRR is priced at $11.04, while STRRP trades at $9.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas STRRP's P/E ratio is -18.28. In terms of profitability, STRR's ROE is -0.14%, compared to STRRP's ROE of -0.14%. Regarding short-term risk, STRR is less volatile compared to STRRP. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check STRRP's competition here
STRR vs PRPO Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, PRPO has a market cap of 41M. Regarding current trading prices, STRR is priced at $11.04, while PRPO trades at $22.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas PRPO's P/E ratio is -16.40. In terms of profitability, STRR's ROE is -0.14%, compared to PRPO's ROE of -0.07%. Regarding short-term risk, STRR is less volatile compared to PRPO. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check PRPO's competition here
STRR vs AKU Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, AKU has a market cap of 26.3M. Regarding current trading prices, STRR is priced at $11.04, while AKU trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas AKU's P/E ratio is -0.13. In terms of profitability, STRR's ROE is -0.14%, compared to AKU's ROE of -5.32%. Regarding short-term risk, STRR is less volatile compared to AKU. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check AKU's competition here
STRR vs MDXH Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, MDXH has a market cap of 24.9M. Regarding current trading prices, STRR is priced at $11.04, while MDXH trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas MDXH's P/E ratio is -1.28. In terms of profitability, STRR's ROE is -0.14%, compared to MDXH's ROE of +4.03%. Regarding short-term risk, STRR is less volatile compared to MDXH. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check MDXH's competition here
STRR vs QUCY Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, QUCY has a market cap of 18.4M. Regarding current trading prices, STRR is priced at $11.04, while QUCY trades at $1.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas QUCY's P/E ratio is -0.07. In terms of profitability, STRR's ROE is -0.14%, compared to QUCY's ROE of -2.44%. Regarding short-term risk, STRR is less volatile compared to QUCY. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check QUCY's competition here
STRR vs CEMI Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, CEMI has a market cap of 16.7M. Regarding current trading prices, STRR is priced at $11.04, while CEMI trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas CEMI's P/E ratio is -0.63. In terms of profitability, STRR's ROE is -0.14%, compared to CEMI's ROE of -0.89%. Regarding short-term risk, STRR is more volatile compared to CEMI. This indicates potentially higher risk in terms of short-term price fluctuations for STRR.Check CEMI's competition here
STRR vs ENZ Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, ENZ has a market cap of 16.4M. Regarding current trading prices, STRR is priced at $11.04, while ENZ trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas ENZ's P/E ratio is -2.24. In terms of profitability, STRR's ROE is -0.14%, compared to ENZ's ROE of -0.10%. Regarding short-term risk, STRR is less volatile compared to ENZ. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check ENZ's competition here
STRR vs PMD Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, PMD has a market cap of 15.6M. Regarding current trading prices, STRR is priced at $11.04, while PMD trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas PMD's P/E ratio is -5.24. In terms of profitability, STRR's ROE is -0.14%, compared to PMD's ROE of -0.32%. Regarding short-term risk, STRR is more volatile compared to PMD. This indicates potentially higher risk in terms of short-term price fluctuations for STRR.Check PMD's competition here
STRR vs ME Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, ME has a market cap of 15.3M. Regarding current trading prices, STRR is priced at $11.04, while ME trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas ME's P/E ratio is -0.03. In terms of profitability, STRR's ROE is -0.14%, compared to ME's ROE of -7.71%. Regarding short-term risk, STRR is more volatile compared to ME. This indicates potentially higher risk in terms of short-term price fluctuations for STRR.Check ME's competition here
STRR vs MYNZ Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, MYNZ has a market cap of 14.7M. Regarding current trading prices, STRR is priced at $11.04, while MYNZ trades at $3.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas MYNZ's P/E ratio is -0.68. In terms of profitability, STRR's ROE is -0.14%, compared to MYNZ's ROE of -10.25%. Regarding short-term risk, STRR is less volatile compared to MYNZ. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check MYNZ's competition here
STRR vs BNGO Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, BNGO has a market cap of 13M. Regarding current trading prices, STRR is priced at $11.04, while BNGO trades at $1.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas BNGO's P/E ratio is -0.26. In terms of profitability, STRR's ROE is -0.14%, compared to BNGO's ROE of -0.71%. Regarding short-term risk, STRR is less volatile compared to BNGO. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check BNGO's competition here
STRR vs CHEK Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, CHEK has a market cap of 10.9M. Regarding current trading prices, STRR is priced at $11.04, while CHEK trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas CHEK's P/E ratio is -0.43. In terms of profitability, STRR's ROE is -0.14%, compared to CHEK's ROE of -2.26%. Regarding short-term risk, STRR is less volatile compared to CHEK. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check CHEK's competition here
STRR vs CNTG Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, CNTG has a market cap of 9.4M. Regarding current trading prices, STRR is priced at $11.04, while CNTG trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas CNTG's P/E ratio is -0.23. In terms of profitability, STRR's ROE is -0.14%, compared to CNTG's ROE of +3.98%. Regarding short-term risk, STRR is more volatile compared to CNTG. This indicates potentially higher risk in terms of short-term price fluctuations for STRR.Check CNTG's competition here
STRR vs BNR Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, BNR has a market cap of 9M. Regarding current trading prices, STRR is priced at $11.04, while BNR trades at $8.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas BNR's P/E ratio is -10.39. In terms of profitability, STRR's ROE is -0.14%, compared to BNR's ROE of -0.11%. Regarding short-term risk, STRR is less volatile compared to BNR. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check BNR's competition here
STRR vs MBAI Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, MBAI has a market cap of 7.5M. Regarding current trading prices, STRR is priced at $11.04, while MBAI trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas MBAI's P/E ratio is 1.93. In terms of profitability, STRR's ROE is -0.14%, compared to MBAI's ROE of +4.17%. Regarding short-term risk, STRR is less volatile compared to MBAI. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check MBAI's competition here
STRR vs APDN Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, APDN has a market cap of 7.3M. Regarding current trading prices, STRR is priced at $11.04, while APDN trades at $5.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas APDN's P/E ratio is -0.10. In terms of profitability, STRR's ROE is -0.14%, compared to APDN's ROE of -6.53%. Regarding short-term risk, STRR is less volatile compared to APDN. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check APDN's competition here
STRR vs VNRX Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, VNRX has a market cap of 7.2M. Regarding current trading prices, STRR is priced at $11.04, while VNRX trades at $1.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas VNRX's P/E ratio is -0.29. In terms of profitability, STRR's ROE is -0.14%, compared to VNRX's ROE of +0.74%. Regarding short-term risk, STRR is less volatile compared to VNRX. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check VNRX's competition here
STRR vs NVTA Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, NVTA has a market cap of 5.4M. Regarding current trading prices, STRR is priced at $11.04, while NVTA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas NVTA's P/E ratio is -0.00. In terms of profitability, STRR's ROE is -0.14%, compared to NVTA's ROE of -2.02%. Regarding short-term risk, STRR is less volatile compared to NVTA. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check NVTA's competition here
STRR vs ADVB Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, ADVB has a market cap of 5.2M. Regarding current trading prices, STRR is priced at $11.04, while ADVB trades at $4.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas ADVB's P/E ratio is -43.32. In terms of profitability, STRR's ROE is -0.14%, compared to ADVB's ROE of -0.65%. Regarding short-term risk, STRR is less volatile compared to ADVB. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check ADVB's competition here
STRR vs LMDXW Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, LMDXW has a market cap of 5.1M. Regarding current trading prices, STRR is priced at $11.04, while LMDXW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas LMDXW's P/E ratio is -0.00. In terms of profitability, STRR's ROE is -0.14%, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, STRR is less volatile compared to LMDXW. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check LMDXW's competition here
STRR vs LMDX Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, LMDX has a market cap of 5.1M. Regarding current trading prices, STRR is priced at $11.04, while LMDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas LMDX's P/E ratio is -0.01. In terms of profitability, STRR's ROE is -0.14%, compared to LMDX's ROE of -15.58%. Regarding short-term risk, STRR is less volatile compared to LMDX. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check LMDX's competition here
STRR vs NDRA Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, NDRA has a market cap of 4.7M. Regarding current trading prices, STRR is priced at $11.04, while NDRA trades at $6.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas NDRA's P/E ratio is -0.80. In terms of profitability, STRR's ROE is -0.14%, compared to NDRA's ROE of -5.13%. Regarding short-term risk, STRR is less volatile compared to NDRA. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check NDRA's competition here
STRR vs BGLC Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, BGLC has a market cap of 4.2M. Regarding current trading prices, STRR is priced at $11.04, while BGLC trades at $2.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas BGLC's P/E ratio is -1.41. In terms of profitability, STRR's ROE is -0.14%, compared to BGLC's ROE of -0.37%. Regarding short-term risk, STRR is less volatile compared to BGLC. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check BGLC's competition here
STRR vs BIAF Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, BIAF has a market cap of 3.9M. Regarding current trading prices, STRR is priced at $11.04, while BIAF trades at $0.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas BIAF's P/E ratio is -0.18. In terms of profitability, STRR's ROE is -0.14%, compared to BIAF's ROE of -3.59%. Regarding short-term risk, STRR is less volatile compared to BIAF. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check BIAF's competition here
STRR vs BIAFW Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, BIAFW has a market cap of 3.8M. Regarding current trading prices, STRR is priced at $11.04, while BIAFW trades at $0.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas BIAFW's P/E ratio is N/A. In terms of profitability, STRR's ROE is -0.14%, compared to BIAFW's ROE of -3.59%. Regarding short-term risk, STRR is less volatile compared to BIAFW. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check BIAFW's competition here
STRR vs TRIB Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, TRIB has a market cap of 3.6M. Regarding current trading prices, STRR is priced at $11.04, while TRIB trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas TRIB's P/E ratio is -0.17. In terms of profitability, STRR's ROE is -0.14%, compared to TRIB's ROE of +0.68%. Regarding short-term risk, STRR is less volatile compared to TRIB. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check TRIB's competition here
STRR vs DMTK Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, DMTK has a market cap of 3.3M. Regarding current trading prices, STRR is priced at $11.04, while DMTK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas DMTK's P/E ratio is -0.04. In terms of profitability, STRR's ROE is -0.14%, compared to DMTK's ROE of -1.06%. Regarding short-term risk, STRR is less volatile compared to DMTK. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check DMTK's competition here
STRR vs NOTV Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, NOTV has a market cap of 2.8M. Regarding current trading prices, STRR is priced at $11.04, while NOTV trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas NOTV's P/E ratio is -0.03. In terms of profitability, STRR's ROE is -0.14%, compared to NOTV's ROE of -0.75%. Regarding short-term risk, STRR is less volatile compared to NOTV. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check NOTV's competition here
STRR vs SQL Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, SQL has a market cap of 2.5M. Regarding current trading prices, STRR is priced at $11.04, while SQL trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas SQL's P/E ratio is -0.40. In terms of profitability, STRR's ROE is -0.14%, compared to SQL's ROE of +38.02%. Regarding short-term risk, STRR is less volatile compared to SQL. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check SQL's competition here
STRR vs AWH Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, AWH has a market cap of 2.5M. Regarding current trading prices, STRR is priced at $11.04, while AWH trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas AWH's P/E ratio is -0.09. In terms of profitability, STRR's ROE is -0.14%, compared to AWH's ROE of +2.03%. Regarding short-term risk, STRR is more volatile compared to AWH. This indicates potentially higher risk in terms of short-term price fluctuations for STRR.Check AWH's competition here
STRR vs INBS Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, INBS has a market cap of 1.4M. Regarding current trading prices, STRR is priced at $11.04, while INBS trades at $2.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas INBS's P/E ratio is -0.26. In terms of profitability, STRR's ROE is -0.14%, compared to INBS's ROE of -1.74%. Regarding short-term risk, STRR is less volatile compared to INBS. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check INBS's competition here
STRR vs HTGM Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, HTGM has a market cap of 1.1M. Regarding current trading prices, STRR is priced at $11.04, while HTGM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas HTGM's P/E ratio is -0.03. In terms of profitability, STRR's ROE is -0.14%, compared to HTGM's ROE of -2.73%. Regarding short-term risk, STRR is more volatile compared to HTGM. This indicates potentially higher risk in terms of short-term price fluctuations for STRR.Check HTGM's competition here
STRR vs BIOC Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, BIOC has a market cap of 450.8K. Regarding current trading prices, STRR is priced at $11.04, while BIOC trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas BIOC's P/E ratio is -0.01. In terms of profitability, STRR's ROE is -0.14%, compared to BIOC's ROE of -1.38%. Regarding short-term risk, STRR is less volatile compared to BIOC. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check BIOC's competition here
STRR vs ISPC Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, ISPC has a market cap of 372.2K. Regarding current trading prices, STRR is priced at $11.04, while ISPC trades at $2.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas ISPC's P/E ratio is -0.09. In terms of profitability, STRR's ROE is -0.14%, compared to ISPC's ROE of -5.85%. Regarding short-term risk, STRR is less volatile compared to ISPC. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check ISPC's competition here
STRR vs PRENW Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, PRENW has a market cap of 195.6K. Regarding current trading prices, STRR is priced at $11.04, while PRENW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas PRENW's P/E ratio is N/A. In terms of profitability, STRR's ROE is -0.14%, compared to PRENW's ROE of -0.47%. Regarding short-term risk, STRR is less volatile compared to PRENW. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check PRENW's competition here
STRR vs SQLLW Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, SQLLW has a market cap of 164.5K. Regarding current trading prices, STRR is priced at $11.04, while SQLLW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas SQLLW's P/E ratio is -0.01. In terms of profitability, STRR's ROE is -0.14%, compared to SQLLW's ROE of +38.02%. Regarding short-term risk, STRR is less volatile compared to SQLLW. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check SQLLW's competition here
STRR vs DHR-PA Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, DHR-PA has a market cap of 0. Regarding current trading prices, STRR is priced at $11.04, while DHR-PA trades at $1,841.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas DHR-PA's P/E ratio is 233.57. In terms of profitability, STRR's ROE is -0.14%, compared to DHR-PA's ROE of +0.07%. Regarding short-term risk, STRR is less volatile compared to DHR-PA. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check DHR-PA's competition here
STRR vs OCDX Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, OCDX has a market cap of 0. Regarding current trading prices, STRR is priced at $11.04, while OCDX trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas OCDX's P/E ratio is -42.28. In terms of profitability, STRR's ROE is -0.14%, compared to OCDX's ROE of +0.18%. Regarding short-term risk, STRR is more volatile compared to OCDX. This indicates potentially higher risk in terms of short-term price fluctuations for STRR.Check OCDX's competition here
STRR vs PRXL Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, PRXL has a market cap of 0. Regarding current trading prices, STRR is priced at $11.04, while PRXL trades at $88.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas PRXL's P/E ratio is N/A. In terms of profitability, STRR's ROE is -0.14%, compared to PRXL's ROE of +0.17%. Regarding short-term risk, STRR is more volatile compared to PRXL. This indicates potentially higher risk in terms of short-term price fluctuations for STRR.Check PRXL's competition here
STRR vs BNGOW Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, BNGOW has a market cap of 0. Regarding current trading prices, STRR is priced at $11.04, while BNGOW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas BNGOW's P/E ratio is N/A. In terms of profitability, STRR's ROE is -0.14%, compared to BNGOW's ROE of -0.71%. Regarding short-term risk, STRR is less volatile compared to BNGOW. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check BNGOW's competition here
STRR vs MEUSW Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, MEUSW has a market cap of 0. Regarding current trading prices, STRR is priced at $11.04, while MEUSW trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas MEUSW's P/E ratio is N/A. In terms of profitability, STRR's ROE is -0.14%, compared to MEUSW's ROE of -7.71%. Regarding short-term risk, STRR is less volatile compared to MEUSW. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check MEUSW's competition here
STRR vs NDRAW Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, NDRAW has a market cap of 0. Regarding current trading prices, STRR is priced at $11.04, while NDRAW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas NDRAW's P/E ratio is N/A. In terms of profitability, STRR's ROE is -0.14%, compared to NDRAW's ROE of -5.13%. Regarding short-term risk, STRR is less volatile compared to NDRAW. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check NDRAW's competition here
STRR vs CHEKZ Comparison June 2026
STRR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STRR stands at 40.9M. In comparison, CHEKZ has a market cap of 0. Regarding current trading prices, STRR is priced at $11.04, while CHEKZ trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STRR currently has a P/E ratio of -11.64, whereas CHEKZ's P/E ratio is N/A. In terms of profitability, STRR's ROE is -0.14%, compared to CHEKZ's ROE of +4.17%. Regarding short-term risk, STRR is less volatile compared to CHEKZ. This indicates potentially lower risk in terms of short-term price fluctuations for STRR.Check CHEKZ's competition here